Adverse Drug Reaction Classification System

ADR Ontology
ADR Term Metastases to ovary
ADR ID BADD_A10420
ADR Hierarchy
16      Neoplasms benign, malignant and unspecified (incl cysts and polyps)
16.22      Metastases
16.22.02      Metastases to specified sites
16.22.02.037      Metastases to ovary
21      Reproductive system and breast disorders
21.11      Ovarian and fallopian tube disorders
21.11.01      Ovarian and fallopian tube cysts and neoplasms
21.11.01.019      Metastases to ovary
Description Mucocellular carcinoma of the ovary, usually metastatic from the gastrointestinal tract, characterized by areas of mucoid degeneration and the presence of signet-ring-like cells. It accounts for 30%-40% of metastatic cancers to the ovaries and possibly 1%-2% of all malignant ovarian tumors. The lesions may not be discovered until the primary disease is advanced, and most patients die of their disease within a year. In some cases, a primary tumor is not found. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1685) [MeSH]
MedDRA Code 10027462
MeSH ID D007725
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Metastases to ovary | Ovarian metastases | Secondary malignant neoplasm of ovary | Krukenberg tumour | Krukenberg tumor | Krukenberg Tumor | Tumor, Krukenberg | Krukenberg Carcinoma | Carcinoma, Krukenberg | Krukenberg's Tumor | Krukenbergs Tumor | Tumor, Krukenberg's
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D01257Letrozole0.000263%
BADD_D02344Vemurafenib0.000112%
BADD_D02412Octreotide--
The 1th Page    1    Total 1 Pages